Benitec’s abandoned one-dose hep C “cure” actually had two big problems
Back in February execs at the Sydney-based microcap biotech Benitec Biopharma $BNTC told their investors that they were going to drop their hepatitis C therapy because they felt that the market opportunities had dried up after a series of game-changing therapies were introduced. Now they’re also conceding another little problem with the treatment: It didn’t actually work.
The main goal for their Phase I/IIa study, the lead effort in its pipeline, was determining the safety of the therapy, which they say investigators clearly hit. However, it also didn’t have any kind of appreciable effect on viral load.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
